Navigation Links
Statin Use Doesn't Inhibit Lymphoma Drug Therapy
Date:12/9/2008

Cholesterol-lowering meds may actually help patients on rituximab, study suggests

TUESDAY, Dec. 9 (HealthDay News) -- Cholesterol-lowering statin drugs don't interfere with rituximab, a medication used to treat lymphomas, say Mayo Clinic researchers, who also found that statins may actually slow progression of some kinds of lymphomas.

Rituximab is a monoclonal antibody often used alone or in conjunction with chemotherapy to treat lymphomas -- cancers of the lymph system. A study published earlier this year suggested that statins may inhibit rituximab's ability to bind to CD20, a protein found on lymphoma cells.

"That finding raised questions about maintaining or stopping cholesterol treatment with statins for patients with lymphoma," Mayo hematologist Dr. Grzegorz Nowakowski said in a clinic news release. "One in five lymphoma patients take cholesterol-lowering statins. This corresponds to the potential for thousands of patients at risk of getting less or ineffective treatment due to statin interference with therapy."

To clarify the issue, the Mayo team studied 228 patients with aggressive diffuse large B-cell lymphoma and 293 patients with slowly progressive follicular lymphoma. Twenty-two percent of the patients with diffuse large B-cell lymphoma and 19 percent of patients with follicular lymphoma were taking statins when they began treatment for their lymphoma.

Statin use didn't influence outcomes for patients with diffuse large B-cell lymphoma. Among the patients with follicular lymphoma, those taking statins actually had better outcomes. At two years, 80 percent of follicular lymphoma patients taking statins had no progression or re-treatment for their cancer, compared with 69 percent of patients not taking statins. This positive effect was observed regardless of the type of treatment: observation only; rituximab alone; or rituximab in combination with chemotherapy.

The study was expected to be presented Monday at the annual meeting of the American Society of Hematology, in San Francisco.

"These results can provide reassurance to oncologists and their patients that statins will not reduce the effectiveness of rituximab (brand name Rituxan) and may in fact improve outcomes of some patients with lymphomas," Nowakowski said.

More information

The Lymphoma Research Foundation has more about lymphoma.



-- Robert Preidt



SOURCE: Mayo Clinic, news release, Dec. 8, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Continued Statin Use Boosts Post-Stroke Outcomes
2. Stopping Statins After Stroke Doubles Death Risk
3. Research to shed new light on how statins benefit heart patients
4. A New Study Links High Volume Pain Pumps with the Devastating and Painful Loss of Cartilage Following Arthroscopic Shoulder Surgery
5. Statin Benefits Persist After Treatment Stops
6. Statins reduce loss of function, keeping old lungs young - even in smokers
7. Better Prostate Cancer Survival for Men Taking Statins
8. Abbotts Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study
9. Congress called on to replace devastating cuts in Medicare reimbursements by ACP
10. Statins After Bypass Lower Stroke Risk
11. Burn injuries take devastating toll on nations children
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Statin Use Doesn't  Inhibit  Lymphoma Drug Therapy
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital ... area economy by obtaining investment capital for emerging technology companies. SCP has ... have already resulted in more than a million dollars of capital investment for ...
(Date:6/24/2016)... ... June 24, 2016 , ... Finally, a bruise cream that really ... cream can be incorporated into the post-surgical treatment plans of a variety of other ... dermaka cream is very effective for bruising and causes a rapid resolution of bruising ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
Breaking Medicine Technology: